Status:
UNKNOWN
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
Lead Sponsor:
Chinese PLA General Hospital
Collaborating Sponsors:
Jiangsu Suzhong Pharmaceutical Group Co., Ltd.
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Huangkui Capsule is a single medicament of traditional Chinese medicine consists of Abelmoschus manihot and has been widely used to treat kidney disease. The purpose of this study is to evaluate the s...
Detailed Description
The test has not been completed.
Eligibility Criteria
Inclusion
- Clinical diagnosed as non-ESRD chronic kidney disease (stage I-IV)
- Blood pressure of ≤140/90mmHg
- Obtaining the signed informed consent from patients
Exclusion
- Be allergic to Huangkui Capsule
- Combined with severe primary diseases of heart, brain, liver and hematopoietic system and so on, or other serious diseases which can affect the patient's life
- Lactation, pregnancy or plans pregnancy during the study period
- Participating in another clinical study in the same period
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2016
Estimated Enrollment :
1600 Patients enrolled
Trial Details
Trial ID
NCT02231138
Start Date
September 1 2014
End Date
December 1 2016
Last Update
June 1 2016
Active Locations (78)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Hospital of Anhui Medical University
Hefei, Anhui, China, 230000
2
Beijing Military General Hospital
Beijing, Beijing Municipality, China, 100000
3
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100000
4
Dong Zhi Men Hospital of Beijing University of Chinese Medicine
Beijing, Beijing Municipality, China, 100000